NCCN Guidelines® Insights: Soft Tissue Sarcoma, Version 1.2025.
von Mehren M, Kane JM, Armstrong SA, Balach T, Bishop AJ, Buehler D, Carr-Ascher J, Choy E, Cipriano C, Connolly M, Dann A, Davis EJ, Dry S, Eulo V, Ganjoo KN, Gonzalez RJ, De Viveiros PAH, Hitchcock YJ, Kim E, Lefler D, Liebner D, McCarter M, McGarry SV, Mesko NW, Meyer C, Motamedi K, Movva S, Pappo AS, Pollack SM, Poppe M, Riedel RF, Robinson S, Schuetze SM, Sicklick JK, Tseng WW, Weiss MC, Zimel M, Hang LE, Bergman MA, Diwan Z · Journal of the National Comprehensive Cancer Network : JNCCN
Sarcoma subtypes
Abstract
The treatment landscape for soft tissue sarcomas (STS) is evolving constantly. These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for STS specific to surgical management and systemic therapy recommendations for various subtypes.
Shown exactly as published on PubMed. Your oncologist is the right person to judge whether these findings apply to your situation.
Publication type
Source: PubMed, PMID 41671462. Always confirm details with the original publication or your oncologist.